The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey
- PMID: 25996499
- PMCID: PMC4440761
- DOI: 10.1371/journal.pone.0127448
The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey
Abstract
Background: The spread of multi-resistant infections represents a continuously growing problem in cirrhosis, particularly in patients in contact with the healthcare environment.
Aim: Our prospective study aimed to analyze epidemiology, prevalence and risk factors of multi-resistant infections, as well as the rate of failure of empirical antibiotic therapy in cirrhotic patients.
Methods: All consecutive cirrhotic patients hospitalized between 2008 and 2013 with a microbiologically-documented infection (MDI) were enrolled. Infections were classified as Community-Acquired (CA), Hospital-Acquired (HA) and Healthcare-Associated (HCA). Bacteria were classified as Multidrug-Resistant (MDR) if resistant to at least three antimicrobial classes, Extensively-Drug-Resistant (XDR) if only sensitive to one/two classes and Pandrug-Resistant (PDR) if resistant to all classes.
Results: One-hundred-twenty-four infections (15% CA, 52% HA, 33% HCA) were observed in 111 patients. Urinary tract infections, pneumonia and spontaneous bacterial peritonitis were the more frequent. Forty-seven percent of infections were caused by Gram-negative bacteria. Fifty-one percent of the isolates were multi-resistant to antibiotic therapy (76% MDR, 21% XDR, 3% PDR): the use of antibiotic prophylaxis (OR = 8.4; 95%CI = 1.03-76; P = 0,05) and current/recent contact with the healthcare-system (OR = 3.7; 95%CI = 1.05-13; P = 0.04) were selected as independent predictors. The failure of the empirical antibiotic therapy was progressively more frequent according to the degree of resistance. The therapy was inappropriate in the majority of HA and HCA infections.
Conclusions: Multi-resistant infections are increasing in hospitalized cirrhotic patients. A better knowledge of the epidemiological characteristics is important to improve the efficacy of empirical antibiotic therapy. The use of preventive measures aimed at reducing the spread of multi-resistant bacteria is also essential.
Conflict of interest statement
Similar articles
-
Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe.J Hepatol. 2019 Mar;70(3):398-411. doi: 10.1016/j.jhep.2018.10.027. Epub 2018 Nov 2. J Hepatol. 2019. PMID: 30391380
-
Extensively drug-resistant bacteria are an independent predictive factor of mortality in 130 patients with spontaneous bacterial peritonitis or spontaneous bacteremia.World J Gastroenterol. 2016 Apr 21;22(15):4049-56. doi: 10.3748/wjg.v22.i15.4049. World J Gastroenterol. 2016. PMID: 27099449 Free PMC article.
-
Healthcare-associated and nosocomial bacterial infections in cirrhosis: predictors and impact on outcome.Liver Int. 2015 Feb;35(2):391-400. doi: 10.1111/liv.12625. Epub 2014 Jul 21. Liver Int. 2015. PMID: 25039438
-
Multi-resistant bacteria in spontaneous bacterial peritonitis: a new step in management?World J Gastroenterol. 2014 Oct 21;20(39):14079-86. doi: 10.3748/wjg.v20.i39.14079. World J Gastroenterol. 2014. PMID: 25339797 Free PMC article. Review.
-
New antibiotic strategies in patients with cirrhosis and bacterial infection.Expert Rev Gastroenterol Hepatol. 2015;9(12):1495-500. doi: 10.1586/17474124.2015.1100075. Epub 2015 Oct 14. Expert Rev Gastroenterol Hepatol. 2015. PMID: 26465070 Review.
Cited by
-
Prevalence and impact of infections in acute on chronic liver failure in Rishikesh, India: a prospective cohort study.Pan Afr Med J. 2023 Dec 12;46:101. doi: 10.11604/pamj.2023.46.101.39536. eCollection 2023. Pan Afr Med J. 2023. PMID: 38435410 Free PMC article.
-
Impact of bacterial infections prior to liver transplantation on post-transplant outcomes in patients with cirrhosis.JHEP Rep. 2023 Jun 7;5(9):100808. doi: 10.1016/j.jhepr.2023.100808. eCollection 2023 Sep. JHEP Rep. 2023. PMID: 37534231 Free PMC article.
-
Infection prevention and control programme and COVID-19 measures: Effects on hospital-acquired infections in patients with cirrhosis.JHEP Rep. 2023 May;5(5):100703. doi: 10.1016/j.jhepr.2023.100703. Epub 2023 Feb 19. JHEP Rep. 2023. PMID: 36844944 Free PMC article.
-
Norfloxacin prophylaxis effect on multidrug resistance in patients with cirrhosis and bacterial infections.Eur J Clin Microbiol Infect Dis. 2023 Apr;42(4):481-491. doi: 10.1007/s10096-023-04572-2. Epub 2023 Feb 23. Eur J Clin Microbiol Infect Dis. 2023. PMID: 36820931
-
ASEPTIC: primary antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis-study protocol for an interventional randomised controlled trial.Trials. 2022 Sep 27;23(1):812. doi: 10.1186/s13063-022-06727-6. Trials. 2022. PMID: 36167573 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
